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Background: People with vascular risk factors are at increased risk for cognitive impairment 
as well as vascular disease. The objective of this study was to evaluate whether vascular risk 
factor clinical practice guidelines consider cognition as an outcome or in connection with 
treatment compliance.
Methods: Articles from PubMed, EMBASE, and the Cochrane Library were assessed by at 
least two reviewers and were included if: (1) Either hypertension, high cholesterol, diabetes, or 
atrial fibrillation was targeted; (2) The guideline was directed at physicians; (3) Adult patients 
(aged 19 years or older) were targeted; and (4) The guideline was published in English. Of 91 
guidelines, most were excluded because they were duplicates, older versions, or focused on 
single outcomes.
Results: Of the 20 clinical practice guidelines that met inclusion criteria, five mentioned 
cognition. Of these five, four described potential treatment benefits but only two mentioned 
that cognition may affect compliance. No guidelines adequately described how to screen for 
cognitive impairment.
Conclusion: Despite evidence that links cognitive impairment to vascular risk factors, only 
a minority of clinical practice guidelines for the treatment of vascular risk factors consider 
cognition as either an adverse outcome or as a factor to consider in treatment.
Keywords: clinical practice guidelines, evidence-based medicine, vascular risk, cognition, 
target organ damage
As people age, they are more susceptible to dementia and as populations age, the 
dementias generally become more common.1,2 These particularly burdensome illnesses 
have important public health consequences.2,3 As a result, new effort has focused on 
whether dementia is preventable, and in particular whether vascular risk factor control 
might yield this additional benefit.4,5
The idea that vascular risk factor control might prevent dementia is not new. Our 
understanding of the relationship between vascular risk factors and dementia evolved 
from the ancient view that Alzheimer’s disease arose from ‘hardening of the arteries.’ 
That idea gave way in the 1970s to a hard-won conceptual distinction between 
neurodegenerative dementias on the one hand and dementias from vascular causes 
on the other.6 Later, we came again to understand that the two are related,7 as it was 
appreciated that vascular risk factors are not only important for vascular dementias 
but are also risk factors for Alzheimer’s disease.8 Neuropathological studies indicate 
that cerebrovascular pathology and neurodegenerative pathology uncommonly appear Clinical Interventions in Aging 2009:4 426
Rockwood et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
in isolation in elderly people,9,10 and that they can have 
synergistic effect on cognitive impairment,11,12 although this 
need not always be the case.13,14 In addition, dementia and 
atherosclerosis share both risk factors (hypertension, elevated 
cholesterol, diabetes) and pathologic features (inflammatory 
markers, protein mis-folding).15
Given the importance now accorded to vascular risk factors 
in dementia, there is new interest in whether the treatment of 
vascular risk factors might reduce or prevent the incidence of 
dementia. Of note, treatment of hypertension, both in midlife 
and in old age, appears to reduce the risk of cognitive impair-
ment in later life.16–19 Statin therapy is also associated with 
a reduced cognitive decline in patients with elevated serum 
cholesterol, although this relationship has been inconsistent.20 
Physical activity and a mediterranean diet, often advocated to 
lessen risk of vascular disease, are also associated with a reduced 
risk of dementia and cognitive decline.21–24 In consequence, the 
treatment of vascular risk factors prescribed to prevent outcomes 
such as myocardial infarction or renal insufficiency may also 
prevent adverse cognitive outcomes, although whether this 
should be a matter of public health policy is debated.3,4
Against this background, it seems reasonable that clinical 
practice guidelines for the treatment of vascular risk factors 
should include cognition as an aspect of target organ damage, 
even if prevention of damage is not always be possible. Our 
cursory impression was that this is not the case. In conse-
quence, we investigated the extent to which cognition is 
included as an aspect of end-organ damage in clinical practice 
guidelines for the treatment for vascular risk factors. We 
considered cognition in the context of other attributes of the 
guidelines, such as their search strategy and description of 
the search methods.
Methods
Data sources
PubMed, EMBASE, and the Cochrane Library were searched 
for items published between January 1st, 2001 and August 
30th, 2008.
Review methods
Search terms included the medical subject headings 
hypertension, diabetes mellitus, diabetes mellitus – type 2, 
hypercholesterolemia, hypercholesterolemia – familial, and 
atrial fibrillation.
Inclusion criteria
Articles were included if they met the following criteria: 
1. Hypertension, high cholesterol, diabetes, and/or atrial 
fibrillation was targeted; 2. The guideline was directed at 
physicians; 3. Adult patients (aged 19 years or older) were 
targeted; and 4. The guideline was published in English. 
In the case of duplicated or updated guidelines, only the most 
recent clinical practice guideline from a given organization 
or group of authors was considered. Only the unabridged 
versions of duplicated guidelines were reviewed.
Studies were independently evaluated for inclusion by two 
reviewers. Where disagreement arose, a third reviewer came 
to a resolution. We performed an independent assessment of 
both the processes by which guidelines were developed and 
their content with respect to the assessment of end-organ 
damage. To evaluate the process, a quality assessment 
instrument (Supplementary Material A) was developed, 
based on a more general instrument for evaluating the 
quality of consensus guidelines.25 Here, we also noted the 
composition of the review teams and specifically whether they 
included physicians likely to have an interest in cognition. 
To evaluate the content, we developed another standardized 
assessment (Supplementary Material B). We evaluated how 
commonly cognition was mentioned and how frequently 
it was mentioned in comparison with other outcomes. 
In addition to renal disease and claudication, pheochromo-
cytoma was included to compare the inclusion of cognition 
to another disorder that is much less common than cognitive 
impairment but which is traditionally considered in people 
with hypertension.
Results
The initial database search revealed 321 articles for further 
consideration of which only 91 were clinical practice 
guidelines. Once guidelines that were targeted to nonadult 
populations, not aimed at physicians, focused on few or 
only one specific outcomes, or were joint/older versions of 
publications were eliminated, 20 relevant clinical practice 
guidelines remained (Table 1).26–45
Of the 20 clinical practice guidelines that met all criteria, 
five mentioned cognition. Of these five, four discussed 
cognition as an aspect of target organ damage and 
suggested that cognition may benefit from treatment. Two 
discussed cognitive impairment with respect to treatment 
compliance but no guideline thoroughly discussed the 
assessment of cognition. Of the guidelines that mentioned 
cognition, four focused on hypertension and one targeted 
diabetes.
Guidelines that mentioned cognitive impairment as an 
outcome of uncontrolled vascular risk factors were more 
likely to have mentioned claudication and renal function. Clinical Interventions in Aging 2009:4 427
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A larger portion of the guidelines that mentioned cognition 
also included descriptive studies in the evidence and provided 
a description of the authors. Studies that cited cognition were 
also less likely to describe the search strategy and explicitly 
link evidence to the strength of the guidelines (Table 2).
Discussion
The number of people diagnosed with dementia is expected to 
surge in the upcoming decades largely because of more people 
living to an age where dementia is common.1,2 As a result, the 
prevention of dementia has emerged as a major public health 
focus46 and vascular risk factor control is one of the most 
promising factors for the prevention of dementia.47 Despite 
the strong association between vascular risk factors and 
dementia, this review of current clinical practice guidelines 
for vascular risk factor management indicated that only a 
minority (four of 20) discussed cognition either as an aspect 
of target organ damage or as a consideration in treatment. The 
mention of cognition tended to be idiosyncratic, and unrelated 
to most other measures of the completeness of the guidelines 
or to the processes by which they were achieved.
Our data must be interpreted with caution. Language bias 
could be present because only guidelines published in Eng-
lish were included. However, a guideline from South Africa 
was included along with guidelines from North America and 
Europe and a systematic strategy was followed. In addition, 
our search ended prior to the publication of the Hypertension 
in the Very Elderly Trial data and its analyses of the impact 
of hypertension treatment on cognition.18 While the study 
was not entirely conclusive, the results favored hypertension 
Table 1 Characteristics of clinical practice guidelines included in the review
Association Year Vascular risk factor Target population
American College of Chest Physicians36 2004 Atrial fibrillation Not specified
American Academy of Family Physicians, 
American College of Physicians38
2003 Atrial fibrillation: First-
detected
Adults with first-detected 
atrial fibrillation
American College of Cardiology,   American 
heart   Association, european society of 
Cardiology37
2001 Atrial fibrillation Not specified
California healthcare Foundation,   American 
geriatrics society26
2003 Diabetes Older persons
Us Preventive services Task Force41 2003 Diabetes: diabetes 
mellitus
Adults (diabetes mellitus)
Agencé nationale d’Accréditation et 
d’Évaluation en santé28
2000 Diabetes: type 2 diabetes Type 2 diabetics without 
complications
Canadian Cardiovascular society42 2006 Cholesterol: dyslipidemia
American Diabetes   Association23 2004 Cholesterol: dyslipidemia Adults with diabetes
national Cholesterol education Program30 2002 Cholesterol: high blood 
cholesterol
Adults
American Diabetes   Association24 2004 hypertension Adults with diabetes
American hypertension   Association33 2008 hypertension Adults
Canadian hypertension education Program29 2007 hypertension therapy Adults
Canadian hypertension education Program32 2007 hypertension: diagnosis 
and risk
Adults
european society of hypertension39 2007 hypertension: arterial Not specified
Joint National Committee-727 2003 hypertension: high 
blood pressure
Not specified
national Collaborating Centre for Chronic 
Conditions31
2006 hypertension Not specified
south   African hypertension society34 2006 hypertension Adults
Us Preventative services   Task Force40 2003 hypertension: high 
blood pressure
Adults
Agencé nationale d’Accréditation 
et d’Évaluation en santé25
2005 hypertension Adults
American geriatrics society35 2001 Anticoagulants  
(Warfarin)
Older peopleClinical Interventions in Aging 2009:4 428
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treatment for the benefit of cognition when combined into a 
meta-analysis.18 Future clinical practice guidelines targeting 
hypertension may include cognition in consequence to these 
results.
There is substantial evidence to suggest that people 
who have vascular risk factors are at elevated risk for 
cognitive impairment.15 In addition, there is preliminary 
evidence to suggest that lifestyle modification through 
diet and exercise and the treatment of vascular risk 
factors, particularly hypertension, may partially reduce 
this risk.16–19,23,24 Even so, our study found that few guide-
lines for vascular risk factors mention cognition and even 
fewer make clear recommendations for the screening and 
evaluation of cognitive impairment as an adverse outcome 
of vascular risk factors. As a result, physicians are likely 
to underestimate the cognitive impact of vascular disease. 
Even stroke neurologists have been urged to better recog-
nize cognitive impairment in patients with cerebrovascular 
disease.48
Review procedures that emphasize randomized control 
trials and downgrade evidence from epidemiological stud-
ies often overlook the weaknesses of these trials, such as 
poor validity to clinical populations. In particular, stroke 
guidelines have been criticized for being derived from 
study populations that do not adequately reflect those seen 
in primary care.49 If the outcomes that are important for 
inclusion in clinical practice guidelines are those that most 
impact patients’ lives and well-being, as has been suggested,30 
then cognition is of utmost importance even if the treatment 
evidence is primarily observational and preliminary in 
controlled trials.16–20 That some guidelines described the 
evaluation of pheochromocytoma, but not cognition, suggests 
that the population burden of illness has not always been 
considered of primary importance when developing vascular 
risk factor guidelines.
Dementia guidelines indicate that people with hyper-
tension, hyperlipidemia, and diabetes are at high risk for 
dementia and indicate that for hypertension, treatment will 
reduce this risk.50,51 It follows that clinical practice guidelines 
for the management of vascular risk factors, and particularly 
hypertension, should similarly recommend that practitioners 
consider patients with vascular risk factors to be at high risk 
for cognitive impairment, particularly with patients who 
are at an age (65 years) where cognitive impairment is 
common. Cognitive screening by general practitioners, cardi-
ologists and other physicians has the potential to detect more 
patients in the earliest stages of cognitive impairment and 
dementia, where early detection is important for treatment 
Table 2 A comparison of the vascular risk factor clinical practice guidelines that mentioned cognition (n = 5) to those that did not (n = 15)
Questions Answer Mentioned cognition?
    Yes No
Is there a description of the individuals who were involved in the guidelines development? Yes 
no
4 
5
1 
10
Were there representatives of all relevant disciplines? Yes  
no
3 
3
2 
3
Is the search strategy described? Yes 
no
2 
6
3 
9
Are descriptive studies included? Yes
no
3
7
0
2
Is there a description of the methods used to interpret and asses the strength of the evidence? Yes 
no
2 
12
3 
3
Is there an explicit link between the recommendations and the level of supporting evidence? Yes 
no
3 
14
2 
1
Are recommendations made for ongoing monitoring of condition and complications? Yes 
no
5 
10
0 
5
Does the guideline discuss compliance? Yes 
no
3 
4
2 
11
Does the guideline mention claudication? Yes 
no
4 
2
1 
13
Does the guideline mention renal function? Yes 
no
5 
12
0 
3
Is pheochromocytoma mentioned? Yes 
no
2 
2
3 
13Clinical Interventions in Aging 2009:4 429
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and will become increasingly important as more preventative 
therapies are identified.52
Magnetic resonance imaging (MRI) can provide a detailed 
image of the brain and cerebrovascular system. However, 
the structural changes detected with MRI do not accurately 
predict the clinical manifestation53 of cognitive impairment 
so cognitive testing is imperative. With the development of 
new cognitive testing guidelines,48 which include a 30 minute 
and a 5–10 minute standardized cognitive battery, it is now 
relatively straightforward to administer cognitive testing that 
is more sensitive to vascular cognitive impairment than the 
traditionally used Mini-Mental State Examination (MMSE),54 
which is relatively insensitive to the executive dysfunction 
and subtle memory changes that are important to the 
diagnosis of vascular cognitive impairment.55 Since the five-
minute battery can be administered by study personnel with 
minimal training, including a version that can be administered 
by telephone, it is feasible to include the brief battery for 
clinical screening of patients with vascular risk factors and 
as a measure of cognition in research studies.
Two recent guideline updates offer contrasting evidence 
of progress. The 2007 guidelines for the management of 
arterial hypertension, created jointly by the European Society 
of Hypertension and the European Society of Cardiology,42 
thoroughly describes the evidence linking hypertension to 
the risk of cognitive impairment, unlike its 2003 predecessor. 
Screening for memory impairment is also suggested, though 
the testing procedures are not described (unlike for renal 
disease and pheochromocytoma). The National Collaborating 
Centre for Chronic Conditions, in updating the British 
Society for Hypertension guidelines, however, removed the 
mention of dementia in its 2006 update of the hypertension 
guideline.34 Instead, it describes cerebrovascular disease 
without reference to cognitive impairment as an adverse 
outcome.
Despite the worldwide burden of cardiovascular risk 
factors and their traditionally understood adverse outcomes, 
under-treatment remains an important problem.56 Whether 
realizing that these also increase the risk of dementia 
will prompt people to modify their lifestyles or to seek 
treatment or physicians to initiate treatment is not clear, but 
on a worldwide basis it might provide enough additional 
motivation to make a difference.
Contributions
Kenneth Rockwood, Sandra Black, and Ingmar Skoog 
conceptualized this paper. Laura Middleton, who was a PhD 
student at Dalhousie University when we started the review, 
and Paige Moorhouse did much of the retrieving of papers 
and inter-rater reliability reviews. Dr Sandra, Dr Skoog, 
and I each reviewed one third of the papers. Dr Middleton, 
Dr Moorhouse, and Dr Rockwood wrote the first draft, 
everyone else has revised it. We all approve the submitted 
version.
Funding and acknowledgements
Kenneth Rockwood is supported by the Dalhousie Medical 
Research Foundation as Kathryn Allen Weldon Professor 
of Alzheimer Disease Research. Laura Middleton receives 
support from a Canadian Institute of Health Research 
Fellowship. Paige King Moorhouse holds a Killam Graduate 
Prize from the Killam Trust. Sandra Black receives funds from 
the Canadian Institutes of Health Research, the Alzheimer 
Society of Canada, and the Heart and Stroke Foundation. 
Ingmar Skoog is supported by major grants from The Swedish 
Research Council, Swedish Council for Working Life and 
Social Research, Swedish Brain Power, and LUA/ALF from 
the Sahlgrenska University Hospital.
Disclosures
Within the past five years, Kenneth Rockwood has 
participated in the Third Canadian Consensus Conference 
on the Diagnosis and Treatment of Dementia, and served 
as a paid consultant to the Centers for Disease Control on 
the role of exercise in dementia prevention, and to Pfizer, 
Eisai, Elan/Wyeth, GlaxoSmithKline, Janssen-Ortho, 
Myriad, Numico and Novartis on dementia treatment. He 
is a consultant to a study of dementia treatment for Pfizer. 
Sandra Black has participated in guidelines for stroke and 
dementia and has, within the past five years, served as a paid 
consultant to Pfizer, Janssen-Ortho, Novartis, Lundbeck, 
Myriad Pharmaceuticals, Epix Pharmaceuticals, GlaxoSmith-
Kline, Schering-Plough, Elan and Wyeth Pharmaceuticals. 
She has also received research funds from Novartis 
Pharmaceuticals, Myriad Pharmaceuticals, Eisai-Pfizer, 
Sanofi-Aventis, Boehringer Ingelheim, Novo Nordisk and 
AstraZeneca and speaker’s honoraria from Janssen-Ortho, 
Novartis Pharmaceutical, Lundbeck, Pfizer and Myriad 
Pharmaceuticals. Ingmar Skoog was co-chairman on the 
SCOPE study and received honoraria from AstraZeneca 
for this. Ingmar Skoog has also been on speakers’ bureaus 
for AstraZeneca, Lundbeck, Shire, Esai, Pfizer, Novartis, 
JansenCilag, Bayer, and Organon. None of the authors 
hold stocks in any pharmaceutical company. None of these 
sponsors had any input into the decision to write or the 
content of the paper.Clinical Interventions in Aging 2009:4 430
Rockwood et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
References
  1.  McDowell I. Alzheimer’s disease: insights from epidemiology. Aging. 
2001;13(3):143–162.
  2.  Kalaria RN, Maestre GE, Arizaga R, et al; for World Federation of 
Neurology Dementia Research Group. Alzheimer’s disease and vascular 
dementia in developing countries: prevalence, management, and risk 
factors. Lancet Neurol. 2008;7(9):812–826.
  3.  Stephan BC, Brayne C. Vascular factors and prevention of dementia. 
Int Rev Psychiatry. 2008;20(4):344–356.
  4.  Grodstein F. Cardiovascular risk factors and cognitive function. 
Alzheimers Dement. 2007;3(2 Suppl 1):S16–S22.
  5.  Kivipelto M, Solomon A. Alzheimer’s disease – the ways of prevention. 
J Nutr Health Aging. 2008;12(1):89S–94S.
  6.  Torack RM. The Pathologic Physiology of Dementia. New York, NY: 
Springer; 1978.
  7.  Erkinjuntti T, Hachinski VC. Rethinking vascular dementia. Cerebrovasc 
Dis. 1993;3(1):3–23.
  8.  Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer 
disease. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S106–S114.
  9.  Neuropathology Group of the Medical Research Council Cognitive 
Function and Ageing Study (MRC CFAS). Pathological correlates of 
late-onset dementia in a multicentre, community-based population in 
England and Wales. Lancet. 2001;357(9251):169–175.
10.  Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain 
pathologies account for most dementia cases in community-dwelling 
older persons. Neurology. 2007;69(24):2197–2204.
11.  Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, 
Markesbery WR. Brain infarction and the clinical expression of 
Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813–817.
12.  Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. 
Subcortical infarcts, Alzheimer’s disease pathology, and memory 
function in older persons. Ann Neurol. 2007;62(1):59–66.
13.  Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral 
infarctions and the likelihood of dementia from Alzheimer disease 
pathology. Neurology. 2004;62(7):1148–1155.
14.  Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain 
pathology: vascular origins? Results from the HAAS autopsy study. 
Neurobiol Aging. 2008;29(10):1587–1590.
15.  Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer’s 
disease: inflammation, cholesterol, and misfolded proteins. Lancet. 
2004;363(9415):1139–1146.
16.  Korf ES, White LR, Scheltens P, Launer, LJ. Midlife blood pressure 
and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. 
Hypertension. 2004;44(1):29–34.
17.  Skoog I, Lithell H, Hansson L, et al; for SCOPE Study Group. Effect of 
baseline cognitive function and antihypertensive treatment on cognitive 
and cardiovascular outcomes: Study on Cognition and Prognosis in the 
Elderly (SCOPE). Am J Hypertens. 2005;18(8):1052–1059.
18.  Peters R, Beckett N, Forette F, et al; for HYVET investigators. Incident 
dementia and blood pressure lowering in the Hypertension in the 
Very Elderly Trial cognitive function assessment (HYVET-COG): 
a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8): 
683–689.
19.  Tzourio C, Anderson C, Chapman N, et al; PROGRESS 1 Group. Effects 
of blood pressure lowering with perindopril and indapamide therapy on 
dementia and cognitive decline in patients with cerebrovascular disease. 
Arch Intern Med. 2003;163(9):1069–1075.
20.  Rockwood K. Epidemiological and clinical trials evidence about a 
preventive role for statins in Alzheimer’s disease. Acta Neurol Scand 
Suppl. 2006;185:71–77.
21.  Lautenschlager NT, Almeida OP. Physical activity and cognition in 
old age. Curr Opin Psychiatry. 2006;19(2):190–193.
22.  Rockwood K, Middleton L. Physical activity and the maintenance of 
cognitive function. Alzheimers Dement. 2007;3(2 Suppl 1):S38–S44.
23.  Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, 
and risk of Alzheimer disease. JAMA. 2009;302(6):627–637.
24.  Féart C, Samieri C, Rondeau V , et al. Adherence to a Mediterranean diet, 
cognitive decline, and risk of dementia. JAMA. 2009;302(6):638–648.
25.  Cluzean FA, Littlejohns P, Grimshaw JM, Feder G, Moran SE. 
Development and application of a generic methodology to assess the 
quality of clinical guidelines. Int J Qual Health Care. 1999;11(1):21–28.
26.  Haffner SM. American Diabetes Association. Dyslipidemia management 
in adults with diabetes. Diabetes Care. 2004;27(Suppl 1):S68–S71.
27.  American Diabetes Association. Hypertension management in adults 
with diabetes. Diabetes Care. 2007;27(1 Suppl):S65–S67.
28.  Atlan P, Girerd X, Godin M, Seux ML. Management of Adults with 
Essential Hypertension. Clinical practice recommendations and 
economic data. April 2000. December 7, 2005 update. Available from: 
http://www.anaes.fr/. Accessed August 15, 2008.
29.  Brown AF, Mangione CM, Saliba D, Sarkisian CA; California 
Healthcare Foundation/American Geriatrics Society Panel on Improving 
Care for Elders with Diabetes. Guidelines for improving the care of the 
older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 Suppl 
Guidelines):S265–S280.
30.  Chobanian AV, Bakris GL, Black HR, et al; for Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure; National Heart, Lung, and Blood Institute; and 
National High Blood Pressure Education Program Coordinating Com-
mittee. Seventh report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure. Hyper-
tension. 2003;42(6):1206–1252.
31.  Gay B, Grimaldi A, Guize L, Guliana JM, Masseboeuf N, Selam JL. 
Strategy for management of type 2 diabetics, excluding management 
of complications. March 2001. December 15, 2005 Available from 
http://www.anaes.fr/. Accessed August 15, 2008.
32.  Khan NA, Hemmelgarn B, Padwal R, et al; for Canadian Hypertension 
Education Program. The 2007 Canadian Hypertension Education 
Program recommendations for the management of hypertension: 
Part II – Therapy. Can J Cardiol. 2007;23(7):539–550.
33.  National Cholesterol Education Program. Third Report of the National 
Cholesterol Education Program Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment 
Panel III). September 2002. December 7, 2005. Available from: 
http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Accessed 
August 15, 2008.
34.  The National Collaborating Centre for Chronic Conditions. 
Hypertension. Management in adults in primary care: Pharmological 
update. 2006. October 12, 2007. Available from: http://www.nice.org.
uk/CG034. Accessed August 15, 2008.
35.  Padwal RS, Hemmelgarn BR, McAlister FA, et al; for Canadian 
Hypertension Education Program. The 2007 Canadian Hypertension 
Education Program recommendations for the management of 
hypertension: Part 1 – blood pressure measurement, diagnosis and 
assessment of risk. Can J Cardiol. 2007;23(7):529–538.
36.  Rosendorff C, Black HR, Cannon CP, et al; for American Heart 
Association Council for High Blood Pressure Research; American Heart 
Association Council on Clinical Cardiology; and American Heart Associa-
tion Council on Epidemiology and Prevention. Treatment of Hypertension 
in the Prevention and Management of Ischemic Heart Disease: A Scien-
tific Statement from the American Heart Association Council for High 
Blood Pressure Research and the Councils on Clinical Cardiology and 
Epidemiology and Prevention. Circulation. 2007;115(21):2761–2788.
37.  Seedat YK, Croasdale MA, Milne FJ, et al; for Guideline Committee, 
Southern African Hypertension Society; and Directorate: Chronic 
Diseases, Disabilities and Geriatrics, National Department of Health. 
South African Hypertension Guideline 2006. South African Med J. 
2007;96(4 Pt 2):337–362.
38.  Jacobs LG. The use of oral anticoagulants (warfarin) in older people. 
Am J Geriatr Cardiol. 2003;12(3):153–160.
39.  Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. 
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Con-
ference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 
126(3 Suppl):429–456.Clinical Interventions in Aging 2009:4 431
Vascular risk factor guidelines and cognition Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
40.  Fuster V, Rydén LE, Cannom DS, et al; for American College of 
Cardiology; American Heart Association; and European Society of 
Cardiology. ACC/AHA/ESC Guidelines for the Management of Patients 
with Atrial Fibrillation. J Am Coll Cardiol. 2001;38(4):1266i–xx.
41.  Snow V, Weiss KB, LeFevre M, et al; for AAFP Panel on Atrial 
Fibrillation; and ACP Panel on Atrial Fibrillation. Management of 
newly detected atrial fibrillation: a clinical practice guideline from the 
American Academy of Family Physicians and the American College of 
Physicians. Ann Intern Med. 2003;139(12):1009–1017.
42.  The Task Force for the Management of Arterial Hypertension of the 
European Society of Hypertension (ESH) and of the European Society 
of Cardiology (ESC). Guidelines for the Management of Arterial 
Hypertension. J Hypertens. 2007;25:1105–1187.
43.  US Preventive Services Task Force. Screening for high blood pressure. 
Am J Prev Med. 2003;25(2):159–164.
44.  US Preventive Services Task Force. Screening for type 2 diabetes 
mellitus in adults: recommendations and rationale. Ann Intern Med. 
2003;138(3):212–214.
45.  McPherson R, Frohlich J, Fodor G, Genest J; for Canadian 
Cardiovascular Society. Canadian Cardiovascular Society position 
statement – recommendations for the diagnosis and treatment of dys-
lipidemia and prevention of cardiovascular disease. Can J Cardiol. 
2006;22(12):913–927.
46.  Anderson LA, McConnell SR. The healthy brain and our aging 
population: Translating science to public health practice. Alzheimers 
Dement. 2007;3(2):S1–S2.
47.  Gorelick PB. William M. Feinberg Lecture: Cognitive vitality and 
the role of stroke and cardiovascular disease risk factors. Stroke. 
2005;36(5):975–979.
48.  Hachinski V, Iadecola C, Petersen RC, et al. National Institute of 
Neurological Disorders and Stroke-Canadian Stroke Network vascular 
cognitive impairment harmonization standards. Stroke. 2006;37(9): 
220–224.
49.  Mant J, McManus R, Hare R. Applicability to primary care of national 
clinical guidelines on blood pressure lowering for people with stroke: 
cross sectional study. BMJ. 2006;332(7542):635–637.
50.  Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, 
Sadovnick  AD. Diagnosis and treatment of dementia: 1. Risk assess-
ment and primary prevention of Alzheimer disease. CMAJ. 2008;178(5): 
548–556.
51.  Fillit HM, Doody RS, Binaso K, et al. Recommendations for best 
practices in the treatment of Alzheimer’s disease in managed care. Am J 
Geriatr Pharmacother. 2006;4(Suppl A):S9–S24.
52.  Carrillo MC, Blackwell A, Hampel H, et al. Early risk assessment for 
Alzheimer’s disease. Alzheimers Dement. 2009;5(2):182–196.
53.  Nitkunan A, Barrick TR, Charlton RA, Clark CA, Markus HS. 
Multimodal MRI in cerebral small vessel disease: its relationship with cogni-
tion and sensitivity to change over time. Stroke. 2008;39(7):1999–2005.
54.  Folstein MF, Folstien S, McHugh PR. “Mini-mental state”. A practical 
method for grading the cognitive state of patients for the clinician. 
J Psychiatr Res. 1975;12(3):189–198.
55.  Ingles JL, Boulton DC, Fisk JD, Rockwood K. Preclinical vascular 
cognitive impairment and Alzheimer disease: neuropsychological test 
performance 5 years before diagnosis. Stroke. 2007;38(4):1148–1153.
56.  Bhatt DL, Steg PG, Ohman EM, et al; for REACH Registry 
Investigators. International prevalence, recognition, and treatment of 
cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 
2006;295(2):180–189.Clinical Interventions in Aging 2009:4 432
Rockwood et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Supplementary material   A
Quality of the guideline Y N N/A
1 Are the guidelines peer-reviewed? If no, eliminate from
further review.
2 Is the agency responsible for the development of the
guidelines clearly identified?
3 Was external support received?
4 Did it include pharmaceutical support? If no, skip to 5
4a   •    If pharmaceutical support was received, did the 
company(s) who provided support manufacture or 
distribute drugs that treat cognitive impairment?
5 Is there a description of the individuals who were involved
in the guidelines development? If no, skip to 6
5a   •    If so, were there representatives of all relevant 
disciplines? Comments:
6 Is there a description of the search strategy used to select 
the studies on which the recommendations are based? If no, 
skip to 7
6a   •    If so, does the evidence include descriptive studies as 
well as randomized controlled trials?
7 Is there a description of the method(s) used to interpret 
and assess the strength of the evidence? Comments:
8 Is there an explicit link between the major 
recommendations and the level of supporting evidence? 
Comments:
9 Is there a description of the patients to whom the 
guidelines are meant to apply? Comments:
Supplementary materials
Supplementary material B
Content of the guideline Y N N/A
1 Does the guideline mention claudication?
2 Does the guideline mention cognitive 
impairment? If no, skip to 3.
2a   •    If yes to 2, does the guideline discuss how 
to screen for cognitive impairment?
3 Does the guideline mention renal function? If no, 
skip to 4.
3a   •    If yes to 3, does the guideline discuss how 
to screen for renal function?
4 Does the guideline discuss target organ damage? 
If no, skip to 5.
4a   •    If yes to 4, does the guidelines mention 
cognitive impairment as an aspect of target 
organ damage?
5 Does the guidelines include outcomes? If no, 
skip to 6.
5a   •    If yes to 5, does the guideline mention 
claudication as an outcome?
(Continued)Clinical Interventions in Aging 2009:4
Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treat-
ments intended to prevent or delay the onset of maladaptive correlates 
of aging in human beings. This journal is indexed on PubMed Central, 
MedLine, the American Chemical Society’s ‘Chemical Abstracts 
Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
433
Vascular risk factor guidelines and cognition Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Supplementary material B (Continued)
Content of the guideline Y N N/A
  •    If yes to 5, does the guideline mention 
cognitive impairment as an outcome?
  •    If yes to 5, does the guideline mention renal 
function as an outcome?
6 Does the guideline cite evidence for outcomes 
that are likely to benefit from the recommended 
management? If no, skip to 7.
6a   •    If so, does the guideline cite evidence 
or otherwise suggest that cognition is 
likely to benefit from the recommended 
management?
7 Are recommendations made for ongoing 
monitoring of the principle condition and 
complications? If no, skip to 8.
7a   •    If so, do these recommendations include 
assessment of cognition?
8 Was cognition mentioned as a risk factor 
(exposure) for any vascular outcome? If no, 
skip to 9.